Equities analysts predict that KemPharm, Inc. (NASDAQ:KMPH – Get Rating) will announce $2.24 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for KemPharm’s earnings, with the lowest sales estimate coming in at $2.06 million and the highest estimate coming in at $2.41 million. The firm is […]
KemPharm (NASDAQ:KMPH – Get Rating) will be posting its quarterly earnings results after the market closes on Wednesday, March 30th. Analysts expect KemPharm to post earnings of ($0.08) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. KMPH stock opened at […]
Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product […]
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 KemPharm, Inc. , a specialty. | March 16, 2022
KemPharm Won FDA Approval, But This Analyst Isn t Happy yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.